Radiomics features to distinguish glioblastoma from primary central nervous system lymphoma on multi-parametric MRI
- 19 September 2018
- journal article
- research article
- Published by Springer Nature in Neuroradiology
- Vol. 60 (12) , 1297-1305
Abstract
To determine the feasibility of using high dimensional computer-extracted features, known as radiomics features, in differentiating primary central nervous system lymphoma (PCNSL) from glioblastoma on multi-parametric MR imaging including diffusion-weighted imaging.Keywords
Funding Information
- National Research Foundation of Korea (NRF-2016R1A2B4008545)
- Institute for Basic Science (IBS-R015-D1)
- Ministry of Science and ICT of Korea under the ITRC program (IITP-2018-0-01798)
This publication has 31 references indexed in Scilit:
- Classification of Cerebral Lymphomas and Glioblastomas Featuring Luminance Distribution AnalysisComputational and Mathematical Methods in Medicine, 2013
- Assessment of tumor heterogeneity: an emerging imaging tool for clinical practice?Insights into Imaging, 2012
- Radiomics: Extracting more information from medical images using advanced feature analysisEuropean Journal of Cancer, 2012
- Multiple craniotomies in the management of multifocal and multicentric glioblastomaJournal of Neurosurgery, 2011
- Differentiation between Glioblastomas, Solitary Brain Metastases, and Primary Cerebral Lymphomas Using Diffusion Tensor and Dynamic Susceptibility Contrast-Enhanced MR ImagingAmerican Journal of Neuroradiology, 2011
- Intratumor Heterogeneity Characterized by Textural Features on Baseline 18F-FDG PET Images Predicts Response to Concomitant Radiochemotherapy in Esophageal CancerJournal of Nuclear Medicine, 2011
- Central Nervous System Lymphoma: Characteristic Findings on Traditional and Advanced ImagingAmerican Journal of Neuroradiology, 2010
- Review: Primary CNS lymphomaTherapeutic Advances in Neurological Disorders, 2009
- Diffuse glioma growth: a guerilla warActa Neuropathologica, 2007
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005